[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Caio Júlio César dos Santos Fernandes\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":70},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100627776","long-term-outcomes-of-selexipag-in-schistosomiasis-associated-pulmonary-arterial-hypertension-100627776",false,"NCT07453030","Long-Term Outcomes of Selexipag in Schistosomiasis-Associated Pulmonary Arterial Hypertension","PROPULSE-Sch: Long-Term Evaluation of Selexipag in Schistosomiasis-Associated Pulmonary Arterial Hypertension Using a Propensity Score-Matched Mirror Cohort","PROPULSE-Sch","Inclusion Criteria\n\nAdults aged 18 years or older.\n\n* Confirmed diagnosis of pulmonary arterial hypertension associated with schistosomiasis (PAH-Sch).\n* Diagnosis of pre-capillary pulmonary arterial hypertension confirmed by right heart catheterization, performed at any time prior to the index date (T0), as documented in the medical record.\n* Evidence of schistosomiasis infection, including epidemiological history and ultrasonographic findings compatible with hepatosplenic schistosomiasis.\n* Previous antiparasitic treatment for schistosomiasis.\n* Clinical stability at the index date, defined as absence of progressive right heart failure or clinical worsening within the previous 12 weeks.\n* World Health Organization (WHO) functional class I-III at the index date.\n* Stable background pulmonary arterial hypertension-specific therapy with a phosphodiesterase-5 inhibitor and\u002For endothelin receptor antagonist for at least 12 weeks prior to the index date.\n* For the treated cohort: initiation of oral selexipag as part of routine clinical care.\n* For the mirror cohort: eligibility for therapeutic escalation at the index date without exposure to selexipag.\n\nExclusion Criteria\n\n* World Health Organization (WHO) functional class IV at the index date.\n* Progressive right heart failure or clinical deterioration within the 12 weeks prior to the index date.\n* Documented formal contraindication to selexipag in the medical record.\n* Insufficient baseline data at the index date to allow clinical characterization or inclusion in propensity score analyses.","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","OBSERVATIONAL","Schistosomiasis-associated pulmonary arterial hypertension is a serious condition that can lead to shortness of breath, heart failure, frequent hospitalizations, and early death. Although treatments for pulmonary arterial hypertension have improved over time, patients with this specific cause of the disease are often not included in long-term studies.\n\nSelexipag is an oral medication used to treat pulmonary arterial hypertension and is part of routine clinical care in Brazil. Its long-term effects in patients with schistosomiasis-associated pulmonary arterial hypertension are not well understood.\n\nThe PROPULSE-Sch study aims to evaluate long-term clinical outcomes in patients with schistosomiasis-associated pulmonary arterial hypertension who received selexipag, compared with similar patients who did not receive this medication before it became available at the study center.\n\nThis is an observational study using data from routine medical care. All treatments are prescribed by the treating physicians, and participation in the study does not change patient care. The results may help improve understanding of long-term outcomes and support treatment decisions in this population.",[25],"Pulmonary Arterial Hypertension (PAH)",[27,28,29,30,31,32,33],"Pulmonary Arterial Hypertension","Schistosomiasis","Prostacyclin Pathway","Real-World Evidence","Propensity Score Matching","Long-Term Outcomes","Observational Study","NOT_YET_RECRUITING","2026-02-27",{"date":37,"type":38},"2026-03-05","ACTUAL",{"date":40,"type":21},"2026-03-01",{"date":42,"type":21},"2027-03-01",{"name":44,"class":45},"Caio Júlio César dos Santos Fernandes","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100621721","riociguat-in-triple-therapy-for-pulmonary-arterial-hypertension-in-real-world-practice-100621721","NCT07374302","Riociguat in Triple Therapy for Pulmonary Arterial Hypertension in Real-World Practice","REAPPRAISED: Riociguat in Triple Therapy for Pulmonary Arterial Hypertension - A Single-Center Retrospective Study With Composite Endpoint Evaluation","REAPPRAISED","Inclusion Criteria\n\n* Adults aged 18 years or older.\n* Confirmed diagnosis of pulmonary arterial hypertension (Group 1).\n* Treatment with triple therapy including an endothelin receptor antagonist, a prostacyclin pathway agent, and a phosphodiesterase-5 inhibitor for at least 12 weeks.\n* Switch from a phosphodiesterase-5 inhibitor to riociguat as part of routine clinical care.\n* Availability of minimum data to assess the primary outcome at 6 months.\n\nExclusion Criteria\n\n* Concomitant use of phosphodiesterase-5 inhibitors and riociguat.\n* Inability to confirm vital status or hospitalization outcomes within 6 months.\n* Participation in an interventional clinical trial that mandated the treatment switch.",{"count":56,"type":21},15,"Pulmonary arterial hypertension is a rare and serious disease that can lead to heart failure and early death despite modern treatments. Many patients are treated with a combination of medications targeting different disease pathways, but some continue to have an inadequate response.\n\nRiociguat is a medication that acts on the nitric oxide pathway and may be beneficial in patients who do not respond well to phosphodiesterase-5 inhibitors. In routine clinical practice, some patients receiving triple therapy switch from a phosphodiesterase-5 inhibitor to riociguat.\n\nThe REAPPRAISED study evaluates outcomes in patients with pulmonary arterial hypertension who switched to riociguat while receiving triple therapy. This observational study uses data from routine clinical care and does not involve any experimental treatment. The results may help improve understanding of the effectiveness and safety of this treatment strategy in real-world practice.",[27],[27,60,61,30,62,33],"Riociguat","Triple Therapy","PDE5 Inhibitor Switch","2026-01-24",{"date":65,"type":38},"2026-01-28",{"date":40,"type":21},{"date":68,"type":21},"2026-12-31",{"name":44,"class":45},""]